Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

August 11, 2017: By Jon Swedien
Bausch + Lomb's Stellaris Elite

Bausch + Lomb’s Stellaris Elite

Bausch + Lomb has launched the Stellaris Elite vision enhancement system for retinal surgery in the US, the Bridgewater, New Jersey-based company announced Aug. 7.

The Stellaris Elite platform builds on B+L’s Stellaris PC, a dual-function cataract/vitrectomy machine commercialized in 2010. The FDA gave the Stellaris Elite 501(k) clearance in April.

The new system features the ability to seamlessly integrate future technologies, such as the Vitesse hypersonic vitrectomy system, which will be exclusive to the Stellaris Elite, B+L said.

The Vitesse system is the first and only hypersonic, 100 percent open port vitrectomy platform, B+L said.

Stellaris Elite machines configured for retinal surgery will come equipped with the Vitesse technology, while the Vitesse hand-piece is slated to be released commercially in late 2017.

The Stellaris Elite offers a variety of vitrectomy cutters operating up to 7,500 cuts per minute (cpm), B+L said. The system will feature a new 27-gauge BiBlade vitrectomy cutter that offers cut rates up to 15 thousand cpm and features an open-port design resulting in a higher, more consistent flow rate than single port cutters, B+L said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023